Synergy Empire Limited (SHMY) submitted an amended Form 8-K/A on July 6, 2026, to correct and significantly expand the disclosures around its acquisition of Meluha Therapeutics Berhad. The original agreement was signed in July 2024, and the deal closed on March 28, 2025. This amendment provides the full business description that was missing from the initial filing.
What the company acquired
Synergy Empire purchased all 10 million outstanding shares of Meluha, a private Malaysian biopharmaceutical company. In exchange, it issued 10 million shares of its newly created Series A preferred stock, valued at $0.2155 per share for a total consideration of $2.155 million. Each preferred share carries voting power equal to one common share.
The deal has concentrated voting control. Two former Meluha directors now hold dominant stakes:
- Ramesh A/L Saravanamuthu: 3,359,438 preferred shares, or 29.1% of voting power
- Abdul Jalil bin Jidon: 3,188,437 preferred shares, or 27.7% of voting power
Together, these two shareholders can unilaterally control board elections and any matter requiring shareholder approval.
A complete pivot in business
Before this acquisition, Synergy Empire was a shell-like entity that had recently pivoted to restaurant consultancy services after disposing of its food and beverage subsidiaries. The Meluha deal transforms the company into a biotech operation.
Meluha is a contract manufacturer for cellular therapy and drug discovery. Its two main products are:
- myCell: A regenerative drug derived from umbilical cord mesenchymal stem cells, injected into the knee to treat osteoarthritis.
- Chondrogen: A treatment package combining stem cells with hyaluronic acid for patients with severe knee cartilage defects.
The company has applied for Good Manufacturing Practices certification, expected by July 2026. After that, it plans to begin clinical testing to seek product approvals from Malaysia's Ministry of Health.
Why the amendment matters
The original 8-K filed in 2024 contained only a brief description of the acquisition agreement. This amendment restates the entire filing to include a full corporate history, a detailed business description, an industry overview citing market data, and a comprehensive risk factors section. For investors evaluating the stock, this filing provides the first real look at what Synergy Empire now owns and the risks it faces, including intense competition, reliance on regulatory approvals, and the concentrated voting power of two individuals.